Medical Company Granted FDA Clearance For Netherton Syndrome Clinical Trials

In a significant development that could potentially alter the trajectory of Netherton Syndrome treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) has received clearance from the U.S. Food and Drug Administration (FDA) to include teenage subjects in their ongoing clinical studies. This decision is expected to broaden the scope of the research and pave the way for more comprehensive solutions for Netherton Syndrome. $Quoin Pharmaceuticals(QNRX.US)$